sintilimab + anlotinib + pemetrexed + cisplatin or carboplatin

This is a multi-agent combination regimen consisting of sintilimab, anlotinib, pemetrexed, and either cisplatin or carboplatin. Sintilimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Anlotinib is a small molecule tyrosine kinase inhibitor with antiangiogenic properties, targeting VEGFR 1/2/3, FGFR1–4, PDGFR α/β, and c-Kit. Pemetrexed is an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis. Cisplatin and carboplatin are platinum-based chemotherapeutic agents that induce DNA crosslinking and apoptosis in cancer cells. This four-drug regimen has been investigated as first-line therapy in advanced or metastatic pleural mesothelioma and non-small cell lung cancer (NSCLC), aiming to combine immunotherapy with antiangiogenic therapy and cytotoxic chemotherapy for synergistic antitumor effects[3][4]. The regimen leverages distinct mechanisms—immune modulation by sintilimab, angiogenesis inhibition by anlotinib, antimetabolite action by pemetrexed, and DNA damage induction by platinum agents—to maximize efficacy against aggressive thoracic malignancies.

Brand names

Tyvyt (sintilimab)AL3818 (anlotinib)Alimta (pemetrexed)